Moderna & Merck study: mRNA therapy plus KEYTRUDA cut melanoma recurrence risk by half
The study evaluated patients with stage III/IV melanoma after complete tumor resection
The study evaluated patients with stage III/IV melanoma after complete tumor resection
Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
After leading AstraZeneca's Oncology areas nationally and internationally, Laura Colón will assume the presidency of AstraZeneca in one of its priority global markets
Subscribe To Our Newsletter & Stay Updated